阻断CD276介导的肿瘤特异性细胞毒性T淋巴细胞抑制可能有助于免疫检查点抑制剂实现持久应答
本研究旨在识别介导持久抗黑色素瘤T细胞应答的分子。在持久应答者消退病灶中CD276表达下调,IFN-γ可降低黑色素瘤细胞CD276表达,敲除CD276增强肿瘤浸润淋巴细胞对黑色素瘤细胞的识别和裂解,低CD276表达组抗PD-1治疗后无进展生存有更好趋势,同时抑制PD-L1和CD276可增强体外抗黑色素瘤应答。
要点
- CD276在持久应答者消退病灶中下调,可能参与持久抗肿瘤应答。
- IFN-γ可降低黑色素瘤细胞CD276表达。
- 同时抑制PD-L1和CD276可增强体外抗黑色素瘤T细胞应答。
核心结论
- 抑制CD276信号有潜力增强免疫检查点抑制剂的长期疗效。
研究设计与样本
- 本研究为体外与免疫组化分析,识别并表征介导持久抗黑色素瘤T细胞应答的分子。
主要发现
- CD276在持久应答者消退病灶中表达下调。
- 活化的T细胞释放的IFN-γ可降低黑色素瘤细胞CD276表达。
- 自体共培养实验中,去除黑色素瘤细胞CD276显著增强肿瘤浸润淋巴细胞的识别和裂解。
- 免疫组化分析显示,CD276低表达组抗PD-1治疗后无进展生存有更好趋势。
- 抑制PD-L1和CD276可增强体外肿瘤浸润淋巴细胞的抗黑色素瘤应答。
临床怎么用
- CD276低表达可能作为抗PD-1治疗预后较好的参考指标。
- 联合阻断PD-L1和CD276可能增强抗黑色素瘤T细胞应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most significant advantage of immune checkpoint inhibitors for patients with melanoma is their durable benefits. Particularly, most patients who achieve a complete response maintain a long-term relapse-free survival, even after the cessation of treatment. However, at present, more than half of patients cannot achieve such durable response. Therefore, it is necessary to elucidate mechanisms to achieve durable responses. The objectives of this study are to identify and characterize the molecules that mediate the durable antimelanoma T-cell response. We identified CD276 as a molecule that was downregulated in the regressing lesions of the durable responders. In vitro analysis revealed that exposure to IFN-γ released from activated T cells decreased CD276 expression in melanoma cells. In the autologous coculture assay, the abrogation of CD276 on melanoma cells significantly enhanced recognition and lysis by tumor-infiltrating lymphocytes. An immunohistochemistry analysis showed a tendency toward better progression-free survival after anti-PD-1 therapy in the group with low CD276 expression. We demonstrated that the inhibition of both PD-L1 and CD276 enhanced the antimelanoma response of in vitro tumor-infiltrating lymphocytes. In conclusion, inhibition of CD276 signaling has the potential to enhance the long-term therapeutic efficacy of immune checkpoint inhibitors.
引用
- Aoyama K, Kawashima S, Saeki Y, et al. Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors. J Invest Dermatol. 2026. PMID: 41833709. doi:10.1016/j.jid.2026.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。